[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients - Trial NCT06419361
Access comprehensive clinical trial information for NCT06419361 through Pure Global AI's free database. This Phase 1 trial is sponsored by First Affiliated Hospital of Chongqing Medical University and is currently Not yet recruiting. The study focuses on Stimulator of Interferon Gene,Cancer,Positron Emission Tomography. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
[68Ga]Ga-Sa-DABI-4
Interventional
drug
Sponsor & Location
First Affiliated Hospital of Chongqing Medical University
Timeline & Enrollment
Phase 1
May 21, 2024
Dec 31, 2026
Primary Outcome
Diagnostic efficacy
Summary
Stimulator of interferon gene (STING) protein plays a vital role in the immune surveillance
 of tumor microenvironment. Monitoring STING expression in tumors benefits the relevant STING
 therapy. This study will investigate the safety, biodistribution and potential usefulness of
 a novel 68Ga-labeled agonist ([68Ga]Ga-Sa-DABI-4) for noninvasive positron emission
 tomography (PET) imaging of STING expression in the tumor microenvironment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06419361
Non-Device Trial